Transaction DateRecipientSharesTypePriceValue
17th February 2021Briggs Morrison4,761Open or private purchase$21.00$99,981.00
8th February 2021Briggs Morrison35,156Open or private sale$20.55$722,403.07
8th February 2021Briggs Morrison35,156Exercise of derivative$7.20$253,123.20
3rd February 2021William Meury16,000Grant/award etc.$0.00
3rd February 2021Fabrice Egros16,000Grant/award etc.$0.00
3rd February 2021Jennifer Jarrett16,000Grant/award etc.$0.00
3rd February 2021Pierre Legault16,000Grant/award etc.$0.00
3rd February 2021Keith Katkin16,000Grant/award etc.$0.00
1st February 2021Michael A Metzger15,000Open or private sale$20.19$302,799.00
1st February 2021Michael A Metzger15,000Exercise of derivative$7.20$108,000.00
Syndax Pharmaceuticals
Syndax Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005.

Ticker: SNDX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1395937
Employees: 35
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $54 M (117%)
Assets, Current: $192 M (207%)
Property, Plant and Equipment, Net: $237 Th (-15%)
Other Assets, Noncurrent: $82 Th (-58%)
Assets: $193 M (203%)
Accounts Payable, Current: $2 M (-70%)
Liabilities, Current: $12 M (-32%)
Other Liabilities, Noncurrent: $3 Th (-40%)
Liabilities: $45 M (40%)
Common Stock, Value, Issued: $4 Th (33%)
Common Stock, Shares, Issued: $39 M (41%)
Additional Paid in Capital, Common Stock: $675 M (28%)
Retained Earnings (Accumulated Deficit): $528 M (6%)
Stockholders' Equity (Parent): $148 M (0%)
Liabilities and Equity: $193 M (203%)
Revenue: $379 Th (0%)
Research and Development: $11 M (-46%)
General and Administrative Expenses: $6 M (-49%)
Operating Income/Loss: $17 M (-47%)
Other Income, net: $452 Th (-23%)